Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... and intermediate-1-risk) myelodysplastic syndromes (MDS) with poor prognostic features including anemia and/or ... according to International Working Group 2006 criteria. Secondary endpoints include overall survival, hematologic response including ...

    Research Article last updated 06/23/2016 - 10:17am.

  2. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies ... (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in ...

    Research Article last updated 12/09/2015 - 8:49am.

  3. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    ... of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the ... genes in our training set of 219 patients with MDS or secondary acute myeloid leukemia with findings confirmed in a validation ...

    Research Article last updated 12/08/2015 - 1:04pm.

  4. Eltrombopag Added to IST Yields Encouraging Results

    ... of eltrombopag may impact the risk of clonal evolution to MDS. A small portion (10-20%) of patients with aplastic anemia can develop MDS ... data following transplant. How important are the stated secondary outcomes: overall survival, overall response, relapse, and clonal ...

    Interview last updated 05/24/2017 - 7:44am.

  5. CASCADE (SGN33A-005)

    ... cytologically/histologically confirmed de novo or secondary AML according to World Health Organization (WHO) classification ... chemotherapy for antecedent myelodysplastic syndrome (MDS First Name Last Name ...

    Clinical Trial last updated 06/19/2017 - 2:43pm.

  6. Impact of the revised International Prognostic Scoring System cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndr

    ... in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 03/02/2015 - 2:46pm.

  7. Transplants in Myelodysplastic Syndromes

    ... an increase in the prevalence of de novo but also of secondary forms after prior chemotherapy or radiotherapy, ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 01/20/2015 - 1:10pm.

  8. The Revised International Prognostic Scoring System (IPSS-R) is not Predictive of Survival in Patients with Secondary Myelodysplastic Syndromes

    ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 05/26/2015 - 11:02am.

  9. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms

    ... as a discovery tool in myelodysplastic syndromes (MDS) has led to the identification of a large number of novel mutations. ... and identification of a subset of ancestral and secondary molecular lesions. Chromosomal gains and losses have been ... phenocopy. In addition to the search for somatic defects in MDS, similar discovery studies have been also performed to identify germ line ...

    Research Article last updated 03/03/2015 - 1:30pm.

  10. A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure

    ... (AZA) failure in higher-risk myelodysplastic syndromes (MDS) is poor and new treatment options are needed. Erlotinib, an oral ... or 150mg/day (n=25) of Erlotinib orally after primary or secondary resistance to AZA treatment. Eighteen MDS and 12 AML patients were ...

    Research Article last updated 01/20/2015 - 1:14pm.